Researchers find new indication for cancer drug
French researchers have found MALT1 blockers not only to act on blood cancers but also to be effective as a treatment for glioblastoma.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2153 entries already.
Entries by Thomas Gabrielczyk
Research team improves safety of LGMD2A gene therapy
Researchers have designed a limb girdle muscular dystrophy 2A gene therapy preventing cardiotoxicity of calpain3 gene transfer.
GeNeuro and Karolinska Institute collaborate in multiple sclerosis
Geneva-based GeNeuro SA announced a new clinical study of temelimab to treat patients with multiple sclerosis in collaboration with Karolinska Institute and ASC.
Tecentriq-Avastin combo hits endpoint in liver cancer
Roche AG said on Friday that its PD-L1 blocker Tecentriq plus its VEFG blocker Avastin improved progression-free survival versus sorafinib in a pivotal study in hepatocellular carcinoma (HCC) patients.
Azeria Therapeutics bags €37.3m in Series B financing round
Azeria Therapeutics Ltd (Cambridge, UK) has raised a £32m (€37.3m) in a Series B financing led by Syncona Ltd contributing £29.5m (€34.4m).
GHO capital launches EU’s largest fund ever for life sciences
GHO Capital raises €975m in largest ever European private equity healthcare fund.
Update: BIO-Europe growing further
Europe’s largest partnering event, the BIO-Europe, hit another visitor record on the occasion of its 25th anniversary in Hamburg.
Zelluna Immunotherapy and Glycostem Therapeutics in licence deal
Zelluna Immunotherapy and Glycostem Therapeutics have partnered to develop allogeneic TCR-NK therapies.
Growing sector – growing guide
Thicker than ever: The 21st edition of the Guide to German Biotech Companies has been published. Almost 120 companies from the vibrant biotech sector present themselves in the English-language yearbook.
Novo secures Dicerna’s RNAi liver assets
Danish Novo Nordisk A/S has secured access to Dicerna Inc’s GalXC RNAi technology in a R&D deal worth US$225m upfront over three years comprising 30 liver targets.